CODA Biotherapeutics Names Susan Catalano, Ph.D., as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat intractable neurological disorders, today announced the appointment of Susan...

Click to view original post